Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 3710652, 6 pages
https://doi.org/10.1155/2017/3710652
Research Article

Comparison of the Clinical Characteristics of Pneumocystis Pneumonia between Patients with Rheumatoid Arthritis Being Treated with Biologics and Those Being Treated without Biologics

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

Correspondence should be addressed to Yuko Kaneko; pj.oiek.6z@okenaky

Received 30 January 2017; Accepted 11 June 2017; Published 12 July 2017

Academic Editor: Keiju Hiromura

Copyright © 2017 Mitsuhiro Akiyama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Tasaka and H. Tokuda, “Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies,” Journal of Infection and Chemotherapy, vol. 18, no. 6, pp. 793–806, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. R. M. Selik, E. T. Starcher, and J. W. Curran, “Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends,” AIDS, vol. 1, no. 3, pp. 175–182, 1987. View at Google Scholar · View at Scopus
  3. Y. Kaneko, A. Suwa, Y. Ikeda, and etal., “Pneumocystis jiroveci pneumonia associated with low-dose methotrexate treatment for rheumatoid arthritis: report of two cases and review of the literature,” Modern Rheumatology, vol. 16, no. 1, pp. 36–38, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Mori and M. Sugimoto, “Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis,” Rheumatology, vol. 51, no. 12, pp. 2120–2130, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. E. S. Bruce, L. Kearsley-Fleet, K. D. Watson, and etal., “Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from the british society for rheumatology Biologics Register for Rheumatoid Arthritis,” Rheumatology, vol. 55, no. 7, pp. 1336-1337, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Tanaka, R. Sakai, R. Koike, and M. Harigai, “Pneumocystis jirovecii pneumonia in Japanese patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a pooled analysis of 3 agents,” Journal of Rheumatology, vol. 42, no. 9, pp. 1726–1728, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. P. D. Walzer, M. LaBine, T. J. Redington, and etal., “Lymphocyte changes during chronic administration of and withdrawal from corticosteroids: Relation to Pneumocystis carinii pneumonia,” Journal of Immunology, vol. 133, no. 5, pp. 2502–2508, 1984. View at Google Scholar · View at Scopus
  8. Y. Komano, M. Harigai, and R. Koike, “Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients,” Arthritis Rheumatism, vol. 61, no. 3, pp. 305–12, 2009. View at Publisher · View at Google Scholar
  9. H. Kameda, H. Tokuda, F. Sakai, and etal., “Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of pneumocystis pneumonia in japan revealed by a multicenter study,” Internal Medicine, vol. 50, no. 4, pp. 305–313, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Tasaka, N. Hasegawa, S. Kobayashi, and etal., “Serum indicators for the diagnosis of pneumocystis pneumonia,” Chest, vol. 131, no. 4, pp. 1173–1180, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. C. F. Thomas Jr. and A. H. Limper, “Current insights into the biology and pathogenesis of Pneumocystis pneumonia,” Nature Reviews Microbiology, vol. 5, no. 4, pp. 298–308, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. L. W. Neese, J. E. Standing, E. J. Olson, and etal., “Vitronectin, fibronectin, and gp120 antibody enhance macrophage release of TNF-α in response to Pneumocystis carinii,” Journal of Immunology, vol. 152, no. 9, pp. 4549–4556, 1994. View at Google Scholar · View at Scopus
  13. T. W. Wright, G. S. Pryhuber, P. R. Chess, and etal., “TNF Receptor Signaling Contributes to Chemokine Secretion, Inflammation, and Respiratory Deficits during Pneumocystis Pneumonia,” Journal of Immunology, vol. 172, no. 4, pp. 2511–2521, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Phair, A. Muñoz, R. Detels, and etal., “The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group,” New England Journal of Medicine, vol. 322, no. 3, pp. 161–165, 1990. View at Google Scholar
  15. J. Shellito, V. V. Suzara, W. Blumenfeld, and etal., “A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes,” Journal of Clinical Investigation, vol. 85, no. 5, pp. 1686–1693, 1990. View at Publisher · View at Google Scholar · View at Scopus
  16. A. H. Limper, K. P. Offord, T. F. Smith, and etal., “Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS,” American Review of Respiratory Disease, vol. 140, no. 5, pp. 1204–1209, 1989. View at Publisher · View at Google Scholar · View at Scopus